In this free webinar, learn about advancements in cell line development and glycoengineering. Attendees will gain insights into how precise glycan modulation boosts antibody-dependent cell-mediated cytotoxicity (ADCC) activity and therapeutic efficacy. The featured speaker will share the latest scientific findings driving antibody optimization. The speaker will discuss innovative technologies, such as GlymaxX®, which enable scalable production of afucosylated antibodies.
TORONTO, March 13, 2025 /PRNewswire-PRWeb/ -- Antibody-dependent cell-mediated cytotoxicity (ADCC) is a critical mechanism in antibody therapeutics, enabling the immune system to eliminate cancerous or infected cells. ADCC activity is heavily dependent on glycan patterns, particularly Fc fucosylation levels. Even a 1 percent change in affucosylation makes a significant difference for ADCC. This underscores the immense therapeutic potential of glycosylation control, although replicating and optimizing glycan patterns remains a significant challenge in antibody development for researchers, biopharma companies and contract development and manufacturing organizations (CDMOs).
This webinar will explore how glycoengineering solutions are transforming antibody development by enabling precise control of glycan profiles to optimize ADCC activity. Attendees will gain insights into how innovative technologies streamline workflows, maintain productivity and meet the challenges of scalable production processes. The session will also highlight how these advancements can accelerate the development of biosimilars and next-generation antibody therapeutics.
A major advantage of these technologies is their ability to meet diverse development needs. Biosimilar developers can precisely match originator glycoprofiles to ensure regulatory compliance and therapeutic equivalence while innovators can use precise glycosylation control to design next-generation antibodies with enhanced functionality. These versatile solutions enable the production of afucosylated antibodies to boost ADCC activity or fully fucosylated antibodies for antibody-drug conjugates (ADCs).
During the presentation, the expert speaker will discuss how a highly efficient glyco-engineering technology enables up to 99 percent afucosylation and significantly enhances ADCC activity. Its unique ability to adjust fucosylation levels offers unparalleled flexibility, allowing biopharma companies to produce innovative and potent therapeutics. This proven technology has been applied in late-stage clinical trials and contributed to the FDA approval of antibodies such as zanidatamab and zenocutuzumab.
Register for this webinar to discover how precision glycoengineering can help overcome glycan modulation challenges, optimize ADCC and unlock the full potential of antibody portfolios. Register today to learn how these advancements improve therapeutic outcomes and streamline development processes.
Join Dr. Volker Sandig, Chief Scientific Officer, ProBioGen, for the live webinar on Monday, March 31, 2025, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Enhancing Antibody Therapeutics Through Precision Glycoengineering.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article